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The activation of oncogenes and the inactivation of tumor suppressor genes by mutations
or chronic hepatitis virus infections play key roles in the pathogenesis of hepatocellular
carcinoma (HCC). Here we report that RN181, a really interesting new gene ﬁnger do-
main-containing protein, was down-regulated in highly malignant cell lines and in tumor
cells of 139 HCC clinical samples in comparison with adjacent normal liver tissues. The
expression of RN181 was strongly associated with the pathological grade of HCC. Altera-
tions of the expression of RN181 by retrovirus-transduced up-regulation and short hairpin
RNA–mediated down-regulation demonstrated the function of RN181 as a tumor suppres-
sor because it decreased the proliferation and colony formation of HCC cells in vitro and
inhibited tumor growth in vivo by suppressing cell proliferation and enhancing cell apo-
ptosis in xenografted tumors. Proteomic analyses showed that RN181 regulates the expres-
sion of many proteins that are important in many cellular processes. Statistical analyses
identiﬁed 33 proteins with consistent changes (2-fold) in RN181-transformed cells. Ten
of these proteins were up-regulated by RN181, and 23 were down-regulated. Representa-
tive proteins were validated by western blotting. Interaction network investigations
revealed that 20 RN181-regulated proteins could integrate several key biological processes
such as survival, metabolism, and mitogen-activated protein kinase (MAPK) pathways.
Remarkably, 11 of the 33 proteins are associated with MAPK signaling in one or more
ways. RN181 suppressed the tyrosine phosphorylation of extracellular signal-regulated ki-
nase 1/2 (ERK1/2) in cell lines and in tumor cells of xenografts and HCC clinical samples,
and removing the suppression increased tumor growth. Conclusion: We have shown that
RN181 suppresses the tumorigenesis of HCC through the inhibition of ERK/MAPK sig-
naling in the liver. Our results provide new insights into the pathogenesis of HCC and
may help with the development of novel therapeutic strategies. (HEPATOLOGY
2011;53:1932-1942)
H
epatocellular carcinoma (HCC) is one of the
most common malignant tumors and the
third-leading cause of death from cancer
worldwide with 600,000 deaths per year.1 HCC has
characteristics of rapid growth, early vascular invasion,
and high resistance to standard chemotherapy. For
early or localized disease, surgical resection or liver
transplantation is a curative treatment. However,
approximately 80% of HCC patients present with
advanced disease that is not amenable to surgical
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resection or transplantation and thus have a poor prog-
nosis.2 Recently, in a randomized phase III trial, sora-
fenib, a multikinase inhibitor with potent activity
against v-raf-1 murine leukemia viral oncogene homo-
log 1 (RAF1), v-raf murine sarcoma viral oncogene
homolog B1 (BRAF), vascular endothelial growth fac-
tor receptor 2, vascular endothelial growth factor re-
ceptor 3, c-kit, and platelet-derived growth factor re-
ceptor a (among others),3 was shown to prolong the
median survival time of HCC patients from 7.9 to
10.7 months.4 Signiﬁcantly, this was the ﬁrst time that
a systemic therapy produced clinical beneﬁts in
patients with advanced HCC, and the results will facil-
itate the identiﬁcation of novel targets for the develop-
ment of targeted therapies.
HCC has a complicated molecular tumorigenesis in
which two mechanisms may predominate.5 One is cir-
rhosis associated with hepatic regeneration after tissue
damage caused by a chronic hepatitis B or C virus
infection, chronic alcohol consumption, toxins, or
metabolic inﬂuences. The other includes the activation
of oncogenes and/or inactivation of tumor suppressor
genes by mutations or chronic hepatitis infections.6 In
HCC, frequently mutated genes are those encoding
p53, cyclin-dependent kinase inhibitor 2A, and b-cate-
nin, but deregulated genes include those encoding axis
1, axis 2, v-Ha-ras Harvey rat sarcoma viral oncogene
homolog (HRAS), v-Ki-ras2 Kirsten rat sarcoma viral
oncogene homolog (KRAS), neuroblastoma RAS viral
(v-ras) oncogene homolog, phosphatase and tensin
homolog, hepatocyte nuclear factor 1A, interleukin-6
signal transducer, retinoblastoma 1, SMAD2, SMAD3,
SMAD4, phosphoinositide-3-kinase catalytic alpha
polypeptide (PIK3CA), insulin-like growth factor 2 re-
ceptor, hepatocyte growth factor, hepatocyte growth
factor receptor (MET), colony stimulating factor 1 re-
ceptor, serine/threonine kinase 11, E-cadherin, and cy-
clooxygenase 2.6,7 Both pathogenic mechanisms are
associated with abnormalities in numerous critical cellu-
lar signaling pathways that could perpetuate the tumori-
genic process of HCC.5 One of the major pathways is
mitogen-activated protein kinase (MAPK) signaling. The
mammalian MAPK family consists of extracellular signal-
regulated kinase (ERK), p38, and c-Jun N-terminal kinase
[JNK; also known as stress-activated protein kinase
(SAPK)]. Each of these enzymes has several isoforms:
ERK1 to ERK8; p38a (MAPK14), p38b (MAPK11),
p38c (MAPK12), and p38d (MAPK13); and JNK1
(MAPK8), JNK2 (MAPK9), and JNK3 (MAPK10). Each
MAPK signaling cascade consists of at least three layers: an
MAPK kinase kinase [also known as MAP3K, serine/thre-
onine-speciﬁc protein kinase (RAF), and MEKK], an
MAPK kinase [also known as MAP2K, dual-speciﬁcity
mitogen-activated protein kinase kinase (MEK), and
MKK], and an MAPK. Activated MAPKs phosphorylate
numerous substrates such as cyclin D, c-Myc, p53, activa-
tor protein 1, and c-Jun. Activation of the ERK/MAPK
pathway (also known as the RAF/MEK/ERK pathway),
which can result from the activation of mutations in RAS,
BRAF, and MEK1, the loss of the tumor suppressor neuro-
ﬁbromin 1, or the mutation-mediated upstream activation,
ampliﬁcation, or ligand-mediated activation of cell surface
receptors,8 regulates many important cellular processes
such as proliferation, differentiation, angiogenesis, survival,
and cell adhesion.9 Importantly, the ERK/MAPK pathway
is constitutively activated in HCC (including RAF proto-
oncogene serine/threonine-protein kinase (CRAF),
MEK1/2, and ERK).5
RN181 (also known as HSPC238) is a member of
the family of really interesting new gene ﬁnger pro-
teins, which have been recognized mainly in protein-
protein interactions and protein dimerization.10
RN181 is known to be able to interact with the cyto-
plasmic regulatory domain of integrin aIIbb3 in plate-
lets and contains E3 ubiquitin ligase activity for auto-
ubiquitination.11 However, the physiological substrates
and biological function of RN181 in cancer biology
are unknown. Here we report that RN181 was down-
regulated in tumor cells of clinical HCC samples. The
expression of RN181 was strongly associated with the
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pathological grade. Alterations of RN181 expression
demonstrated the function of RN181 as a tumor sup-
pressor controlling tumor growth in vitro and in vivo.
Proteomic analyses showed that RN181 regulates the
expression of many proteins involved in many impor-
tant cellular processes. A large number of the proteins
are associated with MAPK signaling. We demonstrate
here that ERK/MAPK signaling is the main pathway by
which RN181 suppresses the tumorigenesis of HCC.
Materials and Methods
Cell Culture. Human HCC cell lines (SMMC-
7721, HepG2, and Chang) were purchased from the
Shanghai Institutes for Biological Sciences (China). All
cell lines were cultured in Dulbecco’s modiﬁed Eagle’s
medium supplemented with 10% fetal bovine serum,
100 U/mL penicillin, and 100 lg/mL streptomycin
(complete medium) and were maintained at 37C
with 5% carbon dioxide.
Patients and Tissue Samples. One hundred thirty-
nine clinical tissue samples were collected from HCC
patients who underwent hepatic resection at the Sun
Yat-Sen University Cancer Center from December 2007
to February 2009 and were used in our clinicopathologi-
cal investigation. Patients’ consent and approval by the
local ethics committee were obtained for the use of the
clinical materials in research. They included 128 males
and 11 females with a median age of 50 years (range ¼
21-76 years). Formalin-ﬁxed, parafﬁn-embedded HCC
specimens paired with adjacent nontumor liver tissues
were used for the immunohistochemical study.
Tumor Xenografts. BALB/c nude mice that were 4 to
5 weeks old were purchased from the Experimental Ani-
mal Center of the Guangzhou University of Traditional
Chinese Medicine (China) and were maintained under
standard pathogen-free conditions. Tumor cells (5 
106) in 0.2 mL of serum-free Dulbecco’s modiﬁed Eagle’s
medium were subcutaneously implanted into the ﬂanks
of each mouse. The left ﬂank was implanted with control
tumor cells, whereas the right side was injected with the
tested tumor cells. Each group consisted of six mice.
Tumor growth was monitored by the measurement of
the length and width of the tumor with a caliper. Tumor
sizes were calculated with the following formula:
Size ¼ LengthWidth2  ðp=6Þ
After the mice were sacriﬁced, xenografted tumors
were collected, photographed, and then ﬁxed in paraf-
ﬁn blocks.
Experimental Assays. All experimental assays, includ-
ing quantitative real-time polymerase chain reaction, west-
ern blotting, DNA transfection, cell proliferation and col-
ony formation assays, immunohistochemistry, proteomic
analyses, and statistical analyses, are described in the sup-
porting information.
Results
Production and Characterization of the Anti-
RN181 Antibody. We made a recombinant RN181 pro-
tein and used it to immunize mice for the production of a
speciﬁc antibody. As shown in Fig. 1AB, the immune se-
rum speciﬁcally recognized endogenous RN181 either by
western blotting or by immunochemical staining of nontu-
mor liver tissue. Pre-absorption of the serum with an excess
amount of recombinant RN181 eliminated the antibody-
antigen reaction. RN181 was highly expressed in the
Chang cell line, moderately expressed in the HepG2 cell
line, and weakly expressed in the SMMC-7721 cell line
(Fig. 1C). This suggests that highly malignant tumor cells
may have a lower expression level of RN181.
Expression of RN181 in Clinical HCC Tissues. We
analyzed 139 pairs of HCC and adjacent normal tissues by
immunohistochemistry with the antibody developed in
house. Representative scores of immunohistochemical
staining of RN181 for tumor and stroma cells are shown in
Fig. 2A. As shown in Table 1, RN181 was strongly
expressed in normal tissues adjacent to HCC tissues; all
139 samples of adjacent normal tissues had a score  2þ.
However, in comparison with adjacent normal tissues,
RN181 expression in tumor tissues was signiﬁcantly
decreased (Z ¼ 10.241, P < 0.001). As shown in Fig.
2B, within a tumor, RN181 was highly expressed in normal
stoma cells but was weakly expressed in malignant tumor
cells (representative cases 1 and 2). Interestingly, the expres-
sion of RN181 was strongly associated with the pathologi-
cal grade of HCC (Z¼ 59.138, P < 0.001; Table 1); well-
differentiated tumor cells showed a high level of expression
(cases 1 and 2), whereas poorly differentiated tumor cells
exhibited a low level of expression (case 3). The expression
of RN181 was signiﬁcantly decreased in grade III HCC
tumors versus grade I/II tumors (see Table 1). However,
RN181 expression did not seem to be associated with the
sex, age, or clinical stage of the HCC patients. Thus, the
results suggest that decreased expression of RN181 may be
associated with the tumorigenesis of HCC.
Effects of RN181 on the Proliferation and Colony
Formation of HCC Cells In Vitro. To investigate the
role of RN181 in the tumorigenesis of HCC in vitro,
we up-regulated RN181 in tumor cells by retrovirus-
mediated transduction. RN181 was signiﬁcantly up-
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regulated at both messenger RNA and protein levels in
SMMC-7721/RN181 cells in comparison with control
SMMC-7721/empty cells (Fig. 3A and Supporting
Fig. 1A). 3-(4,5-Dimethylthiazol-2-yl)-2,5-diphenylte-
trazolium bromide (MTT) proliferation assays showed
that up-regulation of RN181 strongly inhibited the
growth of SMMC-7721/RN181 cells in comparison
with control cells (P < 0.01; Fig. 3B). Colony forma-
tion assays demonstrated that up-regulation of RN181
signiﬁcantly reduced the colony formation of SMMC-
7721/RN181 cells in comparison with control cells
(P < 0.01; Fig. 3C). To verify these data, we down-
regulated the expression of endogenous RN181 in
SMMC-7721 cells by the transfection of a short hair-
pin RNA (shRNA)–containing vector. RN181 was sig-
niﬁcantly knocked down at either the messenger RNA
level or the protein level (Fig. 3D and Supporting Fig.
1B). In agreement with the up-regulation results, the
down-regulation of RN181 signiﬁcantly increased the
proliferation (Fig. 3E) and colony formation (Fig. 3F)
of SMMC-7721/knockdown (KD) cells in comparison
with control SMMC-7721/negative control (NC) cells
(P < 0.01). Thus, the results suggest that RN181
functions as a tumor suppressor and thus controls the
growth of HCC cells in vitro.
Effects of RN181 on the Growth of HCC Cells
In Vivo. To determine whether RN181 regulates the
growth of HCC tumors in vivo, we engrafted SMMC-
7721 cells into nude mice (Fig. 4A). Up-regulation of
RN181 (Supporting Fig. 1E) signiﬁcantly decreased
the tumor growth of SMMC-7721/RN181 in compar-
ison with the SMMC-7221/empty control (top panels
in Fig. 4A). Consistently, down-regulation of RN181
(Supporting Fig. 1F) strongly increased the tumor
growth of SMMC-7721/KD in comparison with the
SMMC-7721/NC control (bottom panels in Fig. 4A).
Similar results were observed from xenografted tumors
of Chang cells in which RN181 was knocked down
(Supporting Fig. 2AB).
The immunohistochemistry of tumor sections con-
ﬁrmed the high expression of RN181 at the protein
level in SMMC-7721/RN181 tumors (Fig. 4B). The
cell proliferation of SMMC-7721/RN181 in vivo was
signiﬁcantly decreased (P < 0.01), as demonstrated by
anti–proliferating cell nuclear antigen (anti-PCNA)
staining (middle panels), whereas the cell apoptosis of
SMMC-7721/RN181 was signiﬁcantly increased in
comparison with the cell apoptosis of the control
tumor (P < 0.01), as revealed by anti–activated cas-
pase-3 staining (bottom panels). Consistently, down-
regulation of RN181 increased tumor cell proliferation
and decreased tumor cell apoptosis in SMMC-7721/
KD tumors versus SMMC-7721/NC tumors (Support-
ing Fig. 3). Taken together, these data suggest that
RN181 acts as a tumor suppressor and thus inhibits
the growth of HCC tumors in vivo.
Differential Proteomic Expressions Regulated by
RN181. To explore molecular mechanisms of RN181-
mediated transformation, we performed proteomic
analyses by comparing expression proﬁles of SMMC-
Fig. 1. Characterization of the mouse anti-
RN181 antibody. (A) Western blotting showed
the speciﬁcity of the anti-RN181 antibody.
Recombinant RN181 was used to immunize
the mice (left panel). The recognition of en-
dogenous RN181 in the lysate of Chang cells
by the antibody (middle panel) was fully
removed by pre-absorption of the lysate with
excess recombinant RN181 (right panel). (B)
Immunochemical staining of normal liver tis-
sues with the anti-RN181 antibody. The recog-
nition of endogenous RN181 in liver cells by
the antibody (left panel) was fully absorbed
with excess recombinant RN181. (C) Western
blotting with the anti-RN181 antibody showed
RN181 expression in three liver cancer cell
lines. RN181 was expressed highly in Chang
cells, moderately in HepG2 cells, and weakly
in SMMC-7721 cells. Abbreviation: GAPDH,
glyceraldehyde 3-phosphate dehydrogenase.
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7721/RN181 cells and SMMC-7721/empty cells. Rep-
resentative two-dimensional gel images are shown in
Fig. 5A. More than 1200 spots were detected in each
gel. A number of proteins were regulated by RN181.
According to potential cellular functions, these pro-
teins could be grouped into ﬁve general categories:
actin remodeling and cell migration, cell proliferation
and invasion, apoptosis, metabolism, and signal trans-
duction. Statistical analyses of liquid chromatography/
tandem mass spectrometry data sets revealed 33 pro-
teins from more than 1200 spots showing changes in
abundance (2-fold) with the ratio of SMMC-7721/
RN181 cells to SMMC-7721/empty cells (Supporting
Table 1). Ten of these proteins were signiﬁcantly up-
regulated in SMMC-7721/RN181 cells, whereas 23
were signiﬁcantly down-regulated. The differential
expression changes were reproduced in independent
experiments. Thus, the results suggest that up-regula-
tion of RN181 in tumor cells regulates numerous bio-
logical processes that could suppress the tumorigenesis
of HCC.
To conﬁrm the proteomic results, we validated the
expression of two up-regulated proteins and four down-
regulated proteins by western blotting. As shown in Fig.
5B, the expression levels of enolase 1 (ENO1) and glu-
tathione S-transferase p1 (GSTP1) were signiﬁcantly
increased in SMMC-7721/RN181 cells versus SMMC-
7721/empty cells, whereas the expression levels of tyro-
sine 3-monooxygenase/tryptophan 5-monooxygenase
activation protein epsilon polypeptide (YWHAE), lectin
galactoside-binding soluble 1 (LGALS1), S100 calcium
binding protein A6 (S100A6), and stathmin 1
(STMN1) were decreased in SMMC-7721/RN181 cells
versus SMMC-7721/empty cells.
Regulation of the ERK/MAPK Pathway by
RN181. We investigated interaction networks of 33
proteins obtained from proteomic proﬁling with Osprey
and IntAct. Twenty proteins regulated by RN181 were
shown to integrate several key biological processes such
as survival, metabolism, and MAPK pathways (Fig.
6A). Remarkably, one-third of the identiﬁed proteins
(11/33) are associated with MAPK signaling in one or
more ways [i.e., YWHAE, LGALS1, STMN1, S100A6,
ENO1, GSTP1, nucleophosmin (NPM1), chaperonin
containing TCP1 subunit 3 (CCT3), phosphoglycerate
kinase 1 (PGK1), adenosylhomocysteinase (AHCY),
and nonmetastatic cells 1 (NME1)]; this suggests that
MAPK signaling might be the main pathway by which
RN181 suppresses the tumorigenesis of HCC.
To investigate whether RN181 affects ERK/MAPK
signaling, we performed western blotting with the anti-
body against tyrosine-phosphorylated extracellular sig-
nal-regulated kinase 1/2 (pERK1/2). As shown in Fig.
6B, up-regulation of RN181 (Supporting Fig. 1A)
decreased the pERK1/2 level in SMMC-7721/RN181
cells versus SMMC-7721/empty cells, whereas down-
regulation of RN181 (Supporting Fig. 1B-D) strongly
increased pERK1/2 levels in the SMMC-7721, Chang,
and HepG2 cell lines. However, neither up-regulation
nor down-regulation of RN181 seemed to signiﬁcantly
affect the total ERK1/2 level.
To determine whether the inhibition of the ERK/
MAPK pathway by RN181 contributes to the
Fig. 2. Immunohistochemical analyses of normal liver and HCC tis-
sues in humans. (A) Representative immunostaining scores of RN181
expressed in tumor and stroma cells. Normal liver tissues showed high
expression of RN181 (score ¼ 3þ), whereas HCC tissues showed
moderate (score ¼ 2þ), low (score 1þ), or very week/undetectable
expression (score 0þ) of RN181. (B) Representative immunostaining
of tumor and stroma cells in HCC tissues with different pathological
grades. RN181 was expressed highly in normal liver cells but weakly
in tumor cells (cases 1 and 2). The expression of RN181 was much
higher in well-differentiated HCC cells (case 1) versus poorly differenti-
ated HCC cells (case 3). The original magniﬁcations were 10 (left
panels) and 40 (right panels).
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suppression of tumor growth by RN181, we treated
SMMC-7721 cells with 1,4-diamino-2,3-dicyano-1,4-
bis(2-aminophenylthio)butadiene (U0126), a highly
selective inhibitor of both MEK1 and MEK2.12
U0126 effectively inhibited the tyrosine phosphoryla-
tion of ERK1/2 (Supporting Fig. 4A) and totally abol-
ished the increases in proliferation (Fig. 6C) and col-
ony formation (Fig. 6D and Supporting Fig. 4B)
caused by down-regulation of RN181. Thus, the
results suggest that RN181 suppresses the tumor
Table 1. Correlation of the Expression of RN181 With Clinicopathological Features of 139 Patients With HCC
Feature n
RN181 Expression
Mean Rank Z Value P Value01 11 21 31
Sex
Male 128 19 70 39 70.63 0.693 0.488
Female 11 3 5 3 60.73
Age (years)
<50 69 12 37 20 68.52 0.477 0.633
50 70 10 38 22 71.46
Clinical stage
1 17 5 3 9 76.71 0.744 0.689
2 101 14 59 28 69.50
3 21 3 13 5 67.00
Differentiation
1 25 0 4 21 109.14 59.138 <0.001
2 78 5 52 21 72.64
3 36 17 19 0 37.10
Location
Tumor tissue 139 22 75 42 0 10.241 <0.001
Adjacent tissue 139 0 0 20 119
Fig. 3. Alternations of RN181 expression
modulated the growth and colony formation
of SMMC-7721 cells in vitro. (A) Western
blotting revealed that retrovirus-mediated
transduction up-regulated RN181 in
SMMC-7721 cells at the protein level. (B)
MTT proliferation assays showed that up-
regulation of RN181 inhibited the growth of
SMMC-7721 cells in vitro. (C) Colony for-
mation assays showed that up-regulation of
RN181 inhibited the colony formation of
SMMC-7721 cells in vitro. (D) Western
blotting revealed that transfection of the
shRNA-containing vector down-regulated
RN181 in SMMC-7721 cells at the protein
level. (E) MTT proliferation assays showed
that down-regulation of RN181 increased
the growth of SMMC-7721 cells in vitro. (F)
Colony formation assays showed that
down-regulation of RN181 increased the
colony formation of SMMC-7721 cells
in vitro. Means and standard errors are pre-
sented (n ¼ 4). *P < 0.05 and **P <
0.01. Abbreviations: A570, absorbance at
570 nm; GAPDH, glyceraldehyde 3-phos-
phate dehydrogenase.
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growth of HCC through the inhibition of ERK/
MAPK signaling in tumor cells.
Suppression of ERK/MAPK Signaling by RN181
in Xenografts and HCC Tumors. To investigate
whether the suppressor action of RN181 occurs in vivo,
we analyzed the correlation of RN181 expression with
the ERK/MAPK activity in HCC tumors. As shown in
Fig. 7A, immunohistochemical staining revealed that
up-regulation of RN181 dramatically reduced the
pERK1/2 level in SMMC-7721/RN181 xenografted
tumors versus the SMMC-7721/empty control (top
panels). Consistently, down-regulation of RN181 signif-
icantly increased the pERK1/2 level in SMMC-7721/
KD xenografts versus the SMMC-7721/NC control
(bottom panels). Similar results were obtained from xen-
ografted tumors of Chang cells in which RN181 was
knocked down (Supporting Fig. 2C).
We further evaluated the expression of RN181 and
the ERK/MAPK activity in 40 pairs of HCC clinical
samples. As shown in Fig. 7B, those tumor tissues
with moderate expression of RN181 had a lower level
of pERK1/2, whereas those tumor tissues with low
expression of RN181 displayed a higher level of
pERK1/2 (right panels). In contrast, adjacent normal
liver tissues exhibited high expression of RN181 but
very low or undetectable levels of pERK1/2 (left pan-
els). Pearson correlation analyses showed that RN181
expression was reversely associated with the pERK1/2
levels in HCC tumors (r ¼ 0.432, P < 0.05).
Discussion
The major etiologies of HCC and the risk factors
for its development are well deﬁned, but the
Fig. 4. RN181 suppressed tumor growth
by decreasing tumor cell proliferation and
increasing tumor cell apoptosis in vivo. (A)
Up-regulation of RN181 in SMMC-7721
cells decreased tumor growth in nude
mice, whereas down-regulation of RN181
in SMMC-7721 cells increased tumor
growth in nude mice (paired comparisons).
(B) Up-regulation of RN181 in SMMC-
7721 cells (top panels) decreased tumor
cell proliferation (anti-PCNA staining in the
middle panels) but increased tumor cell
apoptosis (anti–activated caspase-3 stain-
ing in the bottom panels) in xenografted
tumors. Scale bars represent 100 lm;
means and standard errors are presented
(n ¼ 6). *P < 0.05 and **P < 0.01.
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mechanisms of hepatocellular carcinogenesis are still
unclear.6,13 The activation of oncogenes and the loss
of tumor suppressor genes are believed to play key
roles in the pathogenesis of HCC.6 Here we report
that RN181 was down-regulated in highly malignant
cell lines (SMMC-7721 < HepG2 < Chang) and in
tumor cells from 139 HCC clinical samples in com-
parison with adjacent normal liver tissues and stroma
cells within tumors by immunohistochemical staining.
Interestingly, the expression of RN181 was strongly
associated with the pathological grade. These results
suggest that RN181 may control hepatocellular differ-
entiation to suppress the tumorigenesis of HCC.
To investigate the possibility that RN181 could sup-
press the tumorigenesis of HCC, we altered the expres-
sion of RN181 in tumor cells by up-regulation and
down-regulation. We found that up-regulation of
RN181 signiﬁcantly inhibited the growth and colony
formation of SMMC-7721/RN181 cells in vitro; con-
sistently, down-regulation of RN181 enhanced the
growth and colony formation of SMMC-7721/KD
cells in vitro. More importantly, up-regulation of
RN181 decreased the tumor growth of SMMC-7721/
RN181 in vivo, whereas down-regulation of RN181
promoted the tumor growth of both SMMC-7721/
KD and Chang/KD cells by the manipulation of tu-
mor cell proliferation and apoptosis in xenografted
tumors. Taken all these together, we have concluded
that RN181 acts as a tumor suppressor controlling the
tumorigenesis of HCC.
To investigate underlying suppression mechanisms,
we used a high-throughput proteomic approach to
screen global differential expression proﬁles of
SMMC-7721/RN181 and SMMC-7721/empty cells.
We found that RN181 regulated the expression of
many proteins that are important in many cellular
processes. Thirty-three proteins were identiﬁed from
more than 1200 spots showing changes (2-fold) in
RN181-transformed cells versus control cells.
Twenty-three of these proteins were signiﬁcantly
down-regulated by RN181, whereas 10 were signiﬁ-
cantly up-regulated. Interestingly, among the 23
down-regulated proteins, at least 10 molecules
[PGK1,14 guanosine 50-monophosphate synthetase,15
protein arginine methyltransferase 1,16 tropomyosin 3
(TPM3),17 STMN1,18 LGALS1,19 YWHAE,20
S100A6, S100A10, and S100A1121] have been
reported to promote tumorigenesis or tumor progres-
sion. On the other hand, 4 of the 10 up-regulated pro-
teins [AHCY, NME1, histidine triad nucleotide bind-
ing protein 1 (HINT1), and GSTP1] are known to be
involved in suppressing tumorigenesis.22-25 Together,
these data may help to explain why RN181 can sup-
press the tumorigenesis of HCC.
Fig. 5. Proteomic analyses of RN181-regulated proteins. (A) An overview of two-dimensional gel images of SMMC-7721 cells. Highlighted in
circles are the areas in which signiﬁcant and consistent differences in protein expression levels were found between SMMC-7721/RN181 cells
and SMMC-7721/empty cells. (B) Validation of representative proteins obtained from the proteomic analyses by western blotting. ENO1 and
GSTP1 were up-regulated by RN181, whereas YWHAE, LGALS1, S100A6, and STMN1 were down-regulated by RN181. Abbreviations: GAPDH,
glyceraldehyde 3-phosphate dehydrogenase; MW, molecular weight.
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To better understand the mechanisms, we investi-
gated the interaction networks of the 33 proteins identi-
ﬁed from the proteomic analyses. We found that 20
proteins regulated by RN181 could integrate several key
biological processes such as survival, metabolism, and
MAPK pathways. Surprisingly, one-third of the identi-
ﬁed proteins (11/33) are associated with MAPK signal-
ing in one or more ways (i.e., YWHAE, LGALS1,
S100A6, STMN1, ENO1, GSTP1, NPM1, CCT3,
PGK1, AHCY, and NME1). YWHAE, a multifunction
protein of the 14-3-3 family, can activate Ras-mediated
signaling and inhibit cell migration induced by
MEK5.26 LGALS1 is known to activate ERK, JNK,
and activator protein 1. S100A6 can activate JNK.27
STMN1, a substrate of all four isoforms of p38,28 is
highly expressed in HCC and has been associated with
local invasion, early recurrence, and a poor prognosis
for HCC patients.29 ENO1, up-regulated by RN181,
has been shown to bind to the c-Myc promoter and act
as a transcriptional repressor.30 ENO1 can inhibit pros-
tate cancer cell growth by regulating the MEK5-medi-
ated signaling pathway and suppressing nuclear factor
kappa B.31 GSTP1 is capable of protecting cells from
toxins (drugs, pesticides, and carcinogens) and oxidative
stress32 and inhibits tumor necrosis factor receptor-asso-
ciated factor 2 (TRAF2)-induced activation of both
JNK and p38 but not nuclear factor kappa B.33 NPM1,
up-regulated by RN181, can regulate KRAS plasma
membrane interactions and activate ERK/MAPK signal-
ing.34 NME1 can phosphorylate kinase suppressor of
Ras (KSR), a scaffold protein for the MAPK cascade,
and reduce levels of phosphorylated MAPK.35 Consid-
ering all these, we propose that MAPK signaling may
be the major pathway that RN181 regulates in the liver
to suppress the tumorigenesis of HCC.
To verify this hypothesis, we investigated tyrosine
phosphorylation of ERK1/2 because tyrosine phospho-
rylation of ERK1/2 is required to activate the ERK/
Fig. 6. Regulation of the MAPK pathway
by RN181. (A) Analyses of interaction net-
works of RN181-regulated proteins by Os-
prey and IntAct revealed interactions of
RN181-regulated proteins with many biolog-
ical processes. Twenty of 33 proteins that
were identiﬁed as targets of RN181 by pro-
teomic analyses (left side) were shown to
integrate survival, metabolism, and MAPK
pathways (right side). (B) Western blot
analyses of pERK1/2. Up-regulation of
RN181 decreased pERK1/2 levels, whereas
down-regulation of RN181 increased
pERK1/2 levels. Alterations of RN181 did
not affect the total ERK1/2 level. GAPDH
served as a loading control. (C) Increased
cell growth by down-regulation of RN181 in
SMMC-7721 cells was eliminated by the
addition of 20 lM U0126 to the cells cul-
tured in vitro. Means and standard errors
are presented (n ¼ 4). **P < 0.01. (D)
Increased colony formation by down-regula-
tion of RN181 in SMMC-7721 cells was
eliminated by the addition of 20 lM
U0126 to the cells cultured in vitro. Means
and standard errors are presented (n ¼ 4).
**P < 0.01. Abbreviations: GAPDH, glycer-
aldehyde 3-phosphate dehydrogenase; NS,
not signiﬁcant.
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MAPK pathway. Indeed, we revealed that the level of
pERK1/2 was decreased in RN181–up-regulated cells
(SMMC-7721) and increased in RN181–down-regu-
lated cell lines (SMMC-7721, HepG2, and Chang).
Inhibition of ERK/MAPK signaling by U0126 elimi-
nated the increases in proliferation and colony forma-
tion observed in RN181–down-regulated cells and
thus highlighted the role of ERK/MAPK signaling in
RN181 suppressor action for the tumorigenesis of
HCC. Furthermore, we demonstrated that the expres-
sion of RN181 was reversely correlated with the
pERK1/2 level in xenografted tumors and in HCC clin-
ical samples and thus conﬁrmed the relevance of the
ERK/MAPK pathway in the suppression of tumorigen-
esis by RN181 in vivo. It has been noted that the ERK/
MAPK pathway is constitutively activated in HCC
(including CRAF, MEK1/2, and ERK).5 ERK is highly
expressed in tumor tissues and has been signiﬁcantly
correlated with the HCC tumor size.36 ERK1/2 activa-
tion has been associated with aggressive tumor behavior
and can serve as an independent prognostic marker for
decreased overall survival.37 Taken all together, we have
demonstrated that RN181 suppresses the tumorigenesis
of HCC through the inhibition of the ERK/MAPK
pathway in the liver. Clearly, the ways in which RN181
regulates those proteins integrating the ERK/MAPK
pathway and the downstream substrates of ERK/MAPK
signaling that are affected by RN181 in the liver need
to be further investigated in the future.
In summary, we have demonstrated that RN181 is
down-regulated in HCC tumor cells and that the
expression of RN181 is strongly associated with the
pathological grade. In the liver, RN181 functions as a
tumor suppressor to control the tumorigenesis of
HCC because it decreases tumor growth in vitro and
in vivo by suppressing cell proliferation and promoting
cell apoptosis of HCC. Proteomic analyses revealed
that RN181 regulates many proteins involved in sev-
eral important cellular processes such as the MAPK
pathway. RN181 has been shown to suppress ERK/
MAPK signaling, and disrupting this suppression will
increase HCC growth. We conclude that RN181 sup-
presses the tumorigenesis of HCC mainly through the
inhibition of the ERK/MAPK pathway in the liver.
Fig. 7. Suppression of ERK/
MAPK signaling by RN181 in xeno-
grafts and HCC tumors. (A) Up-reg-
ulation of RN181 resulted in a
decrease in the pERK1/2 level (top
panels), whereas down-regulation of
RN181 led to an increase in the
pERK1/2 level (bottom panels) in
SMMC-7721 xenografted tumors.
Means and standard errors are pre-
sented (n ¼ 6). **P < 0.01. (B)
The expression of RN181 was inver-
sely correlated with the pERK1/2
levels in HCC tissues. High expres-
sion of RN181 resulted in low
pERK1/2 levels in adjacent normal
tissues, whereas low expression of
RN181 led to high pERK1/2 levels
in tumor tissues. Means and stand-
ard errors are presented (n ¼ 40).
**P < 0.01.
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Our results provide new insights into the pathogenesis
of HCC and may help with the development of novel
therapeutic strategies.
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